Now ideas for wellness

About Meiji

At a Glance

At a Glance

Get to know Meiji at a glance – from our core business to our most important numbers.

Pipeline

As of 9 November, 2021

  • Clinical Trial
  • Japan
  • Outside of Japan

In-house drug discovery

In-house development

Infectious Diseases

FYE March 2022 FYE March 2023 FYE March 2024
ME1100 Arbekacin inhalation: [HABP/VABP] Phase Ib
OP0595 Nacubactam: [β-lactamase inhibitor] Phase I
with
β-Lactams

More about our work in the field of infectious diseases:

LEARN MORE

CNS Disorders

FYE March 2022 FYE March 2023 FYE March 2024
ME2112 Ziprasidone: [Antipsychotic] *1 Phase III

*1 In-license: RaQualia Pharma Inc.

More about our work in the field of CNS disorders:

LEARN MORE

Others

FYE March 2022 FYE March 2023 FYE March 2024
HBI-8000 Tucidinostat: [Relapsed or refractory Adult T-cell leukemia/lymphoma(ATLL)] *2 Approved
HBI-8000 Tucidinostat: [Relapsed or refractory peripheral T-cell lymphoma (PTCL)] *2 Applied Approve
ME3208 Belumosudil: [Chronic Graft Versus Host Disease] *3 Phase I Phase III
DMB-3115 Ustekinumab biosimilar: [Plaque psoriasis, Psoriatic arthritis, Crohn's disease, Ulcerative colitis] *4 Phase III
DMB-3111 Trastuzumab biosimilar: [Breast cancer, Gastric cancer] *4 (P I finished)
ME3183: [Psoriasis/Selective PDE4 inhibitor] Phase I Phase II

*2 In-license: HUYABIO International, LLC (USA)

*3 Development: Romeck Pharma, LLC

*4 Co-development: Dong-A Socio Holdings Co., Ltd. (South Korea)

Vaccines

FYE March 2022 FYE March 2023 FYE March 2024
KD-370: [Pentavalent vaccine against diphtheria, tetanus, pertussis, polio, and haemophilus influenza type b] Phase III Apply Approve
Phase II
KD-414: [Inactivated vaccine against COVID-19] Phase I / II
Phase II / III
KD-404: [Egg-derived inactivated whole virus influenza vaccine] *5 Phase
I / II
KD-382: [Quadrivalent vaccine against dengue fever] Phase I

*5 Co-development: Hokkaido University

More about our work in the field of vaccines:

LEARN MORE

Blood Plasma Products

FYE March 2022 FYE March 2023 FYE March 2024
KD2-305: [Suppression of bleeding tendency in patients with blood coagulation factor VIII or factor IX deficiency who have coagulation factor inhibitors] Phase II / III Apply Approve
Extension study blank blank

More about our work in the field of blood plasma:

LEARN MORE

Agricultural Chemicals

FYE March 2022 FYE March 2023 FYE March 2024
ME5382: [Insecticide/Flupyrimin] Approved Approved
ME5343: [Insecticide/Afidopyropene] *6 Approved
ANM-138: [Insecticide/Flometoquin] *7 Approved
ME5223: [Fungicide/Fenpicoxamid] *8 Approved

*6 Licensing agreement with BASF

*7 Joint development with Nippon Kayaku

*8 Joint development with Corteva Agriscience

More about our work in the field of agricultural chemicals:

LEARN MORE

Veterinary Drugs

FYE March 2022 FYE March 2023 FYE March 2024
ME4136: [Injectable antibacterial drugs] Approved
ME4137: [Injectable antibacterial drugs] Applied Approve
ME4406: [Feed additive] Apply
ME4204: [Oral anthelmintic] Expanded indication Approved
ME4618: [Anesthetic injection] Applied Approve
ME4624: [Vaccine] Approved
KD-395: [Vaccine for swine use] Applied Approve
KD-386: [Vaccine for swine use] Applied Approve

More about our work in the field of veterinary drugs:

LEARN MORE